Moderna’s Net Zero Pledge
As greenhouse gas concentrations hit a record high last year,¹ climate change is impacting our planet and human health in dramatic ways, including extreme weather contributing to deaths from diseases; air pollution exacerbating respiratory diseases; and climatic conditions increasing the spread of infectious diseases.² On the threshold of COP26, it is clear that time is of the essence to take bold steps to help fight the climate crisis.
Each corporation around the world needs to be part of the solution in addressing climate change. This, combined with changes in consumer behavior and investments in new technology to create clean energy, reduce waste and increase recycling will help accelerate progress for humanity.
By 2030, Moderna will work to achieve net-zero carbon emissions globally. It is critical for a high-growth company like ours to set such a goal, as we aim to put Moderna among the global leaders in managing the impact of waste from our business and decreasing the natural resources we use, to promote long-term, sustainable growth for the planet and our organization.
As we continue through this period of accelerated growth, we will continue to make corporate responsibility a critical part of who we are and what we do with a sense of purpose. From the delivery of our COVID-19 vaccine to our investment in renewable energy, we always seek to do the right thing, the right way.
I am proud of this ambitious goal that we have set for ourselves and look forward to acting with urgency alongside our team, our partners and our communities to achieve it and share best practices along the way. We will build Moderna in a way that minimizes our impact on the planet while delivering innovative vaccines to prevent people from getting sick and medicines to help those who have diseases.
This post contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s goal of achieving net-zero carbon emissions globally by 2030. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.